

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Isodiol International Inc. (the "Issuer")**

Trading Symbol: **ISOL**

Number of Outstanding Listed Securities: **48,274,532**

Date: **May 6, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing, and distribution company of hemp-based consumer products and solutions. It specializes in identifying emerging trends and opportunities from all Cannabinoids available in hemp. The Issuer's growth strategy includes the development of over-the-counter and pharmaceutical drugs and expanding its phytoceutical portfolio by aggressively continuing international expansion into Latin America, Asia, and Europe.

During the month of April 2019, the Issuer actively continued general and corporate operations. Management continued to develop the Issuer's business and search for other strategic business relationships.

2. Provide a general overview and discussion of the activities of management.

On April 1, 2019, the Issuer announced by news release the sale of its wholly-owned subsidiary, BSPG Laboratories Ltd. ("BSPG"), to a U.K.-based private equity group (the "Buyer") for US\$14,000,000 in cash instalments, which provides fiscal year 2020 cash flow financing for the Issuer's consumer packaged goods (CPG) operations. As a part of the transaction, the Issuer has secured an off-take supply agreement with the Buyer to ensure continued distribution of its Purodiol and Isodiolex products.

A first instalment of US\$5,000,000 was paid on March 29, 2019, a second instalment of US\$5,000,000 is due by June 26, 2019, a third instalment of US\$2,000,000 is due by September 26, 2019, and a final instalment of US\$2,000,000 shall be payable upon the expansion of BSPG's production capacity into its newly leased 20,000+ square foot laboratory facility that is expected to increase BSPG's capacity by 8-10 times its current capacity.

In addition, the Issuer announced it has concluded its recent efforts to eliminate certain costly long-term contracts and other liabilities from its balance sheet and future cash flow obligations totalling approximately US\$11,809,539 in exchange for the new issuance of 6,587,170 shares at an average weighted price of CAN\$1.89 per share.

On April 11, 2019, the Issuer announced by news release the commencement of its cannabidiol (CBD) vending machine program with an initial launch of Iso-Sport™ products in 20 Powerhouse Gym ("Powerhouse") locations across the United States. This announcement follows the Issuer's September 14, 2018, announcement that it entered into an agreement with Powerhouse to be the preferred vendor of CBD performance products in Powerhouse gyms.

Powerhouse is one of the largest health club licensing organizations in the world, with over 1.2 million gym members. Today, Powerhouse continues to experience substantial growth opportunities, allowing the Issuer to target a growing consumer base for CBD products.

The Company anticipates its Iso-Sport™ products will be available in vending machines at select Powerhouse gym locations by mid-April 2019.

The above referenced news releases may be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see item 2 with respect to the commencement of the Issuer's cannabidiol (CBD) vending machine program with the initial launch of Iso-Sport™ products in 20 Powerhouse Gym locations across the United States.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of April 2019.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see item 2 with respect to the commencement of the Issuer's cannabidiol (CBD) vending machine program with an initial launch of Iso-Sport™ products in 20 Powerhouse Gym ("Powerhouse") locations across the United States, pursuant to the agreement with Powerhouse to be the preferred vendor of CBD performance products in Powerhouse gyms announced by news release on September 14, 2018.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of April 2019.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see item 2 with respect to the Issuer's sale of its wholly-owned subsidiary, BSPG Laboratories Ltd., to an unrelated U.K.-based private equity group for US\$14,000,000 in cash instalments.

8. Describe the acquisition of new customers or loss of customers.

None to report during the month of April 2019.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report during the month of April 2019.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of April 2019.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of April 2019.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of April 2019.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of April 2019.

14. Provide details of any securities issued and options or warrants granted.

None to report during the month of April 2019.

15. Provide details of any loans to or by Related Persons.

None to report during the month of April 2019.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of April 2019.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis dated March 1, 2019, under the heading "Risk Factors", which can be viewed under the Issuer's profile on SEDAR (www.sedar.com) and on the Issuer's Disclosure Page on the Canadian Securities Exchange's website.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 6, 2019

Eli Dusenbury

Name of Director or Senior Officer

/s/ Eli Dusenbury

Signature

Chief Financial Officer

Official Capacity

<i>Issuer Details</i> Name of Issuer Isodiol International Inc.	For Month End April 2019	Date of Report YY/MM/DD 19/05/06
Issuer Address Suite 2710, 200 Granville Street Vancouver, BC V6C 1S4	Issuer Fax No. 604-608-3348	Issuer Telephone No. 604-409-4409
Contact Name Eli Dusenbury	Contact Position Chief Financial Officer	Contact Telephone No. 604-409-4409
Contact Email Address ir@isodiol.com	Web Site Address www.isodiol.com	